| HOME >> BIOLOGY >> TECHNOLOGY |
BOTHELL, Wash., Feb. 11 /PRNewswire-FirstCall/ -- In response to the recent comments by certain plaintiff law firms regarding their filing of class action lawsuits, CellCyte Genetics Corporation (the "Company") (OTC Bulletin Board: CCYG) asserts that the pending claims are without merit and will be shown to be so in a court of law. To that end, CellCyte has retained the international law firm of Duane Morris LLP as its counsel and will defend itself vigorously in these matters. Concurrently, the Company will continue its commitment to and pursuit of its policy of ensuring that its operations comply with all applicable laws.
"CellCyte is founded on patented technology discovered by and licensed from the US Department of Veteran Affairs. We continue a solid and aggressive development plan for this important technology for the delivery of adult stem cells to the human heart," said Gary A. Reys, Chairman and CEO of CellCyte. "Our highly skilled management and scientific team are committed to developing our technologies to their fullest potential and we continue to be actively involved in collaborations with the Cleveland Clinic and other research leaders".
"Further," Reys said, "CellCyte is actively moving its intellectual properties through the US patent and Trademark office to insure that our technologies are well protected, which is one of the cornerstones of any biotechnology company which helps insure our shareholders a solid and protected technology base. Our most recent patent was issued in November 2007 that covers CellCyte's lead composition. This most recent patent milestone gives CellCyte three fully issued patents."
CellCyte Genetics continues to be actively engaged in carrying out its
business plan and corporate objectives as stated in the company's
literature and filings. This fact is further evidenced by such major
advances as its move to the Company's new 26,000 foot facility and
corporate offices in Bothell Washington and its
'/>"/>
| SOURCE CellCyte Genetics Corporation Copyright©2008 PR Newswire. All rights reserved |